Peptide library › Metabolic & weight
Dasiglucagon
Also known as Zegalogue
Stable, ready-to-use version of glucagon for treating severe low blood sugar in people with diabetes.
What people use it for
- Severe low blood sugar (hypoglycaemia) in diabetes
What Dasiglucagon does in the body
A modified glucagon peptide designed to stay stable as a liquid, so it comes ready to inject with no mixing. Like glucagon, it makes the liver release stored sugar.
Strength of evidence
Strong: Phase 3 trials showed blood sugar recovered within about 10 minutes in most people.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Nausea and vomiting
- Headache
- Injection-site pain
Who should avoid it or take extra care
- Phaeochromocytoma
- Insulinoma
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved in 2021 as Zegalogue for severe hypoglycaemia. Its label has since been updated to use a weight limit rather than an age limit.
How it's taken
Route: Injection under the skin from a prefilled pen or syringe
How long it lasts (half-life): About 30 minutes
Latest research & news
- Charge density effect of micelles on liquid-liquid phase separation
Research · Study · PubMed · Soft Matter · 18 Nov 2026 - Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
Clinical trial · Completed · Phase 3 · Results posted · Updated · ClinicalTrials.gov · 16 Nov 2026
Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.
Keep track of Dasiglucagon privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Dasiglucagon in Fiala How to installMore in Metabolic & weight
- SemaglutideOnce-weekly GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
- TirzepatideOnce-weekly dual GIP and GLP-1 receptor agonist for type 2 diabetes and weight management.
- RetatrutideExperimental triple GIP / GLP-1 / glucagon receptor agonist being studied for obesity.
- AOD-9604Modified fragment of human growth hormone once developed as an anti-obesity drug.
- LiraglutideOnce-daily GLP-1 receptor agonist; the predecessor of semaglutide.
- CagrilintideLong-acting amylin analog being studied for weight loss, mainly combined with semaglutide.
- MazdutideOnce-weekly dual GLP-1 and glucagon receptor agonist for weight management.
- SurvodutideExperimental once-weekly dual glucagon and GLP-1 receptor agonist being studied for obesity and fatty liver disease.
- DulaglutideOnce-weekly GLP-1 receptor agonist approved for type 2 diabetes.
- ExenatideThe first GLP-1 receptor agonist, originally found in Gila monster venom, approved for type 2 diabetes.
- PramlintideSynthetic version of the hormone amylin, used with mealtime insulin in diabetes.
- SetmelanotideMC4R agonist approved for rare genetic causes of severe obesity.
- 5-Amino-1MQSmall molecule sold alongside peptides for fat loss; blocks the enzyme NNMT. Not a peptide, and untested in people.
- AlbiglutideOnce-weekly GLP-1 medicine for type 2 diabetes, discontinued for business reasons in 2018.
- AmycretinExperimental single molecule that acts on both GLP-1 and amylin receptors, tested as a weekly injection and a daily tablet for weight loss.
- EfpeglenatideLong-acting experimental GLP-1 medicine that cut heart and kidney events in people with type 2 diabetes in a large trial.
- LixisenatideOnce-daily GLP-1 medicine for type 2 diabetes, now mainly used in a combined pen with insulin glargine.
- PemvidutideExperimental weekly injection that acts on GLP-1 and glucagon receptors, studied for obesity and fatty liver disease.
- PetrelintideExperimental long-acting amylin analog given weekly for weight loss, aiming for fewer stomach side effects than GLP-1 drugs.
- Insulin analogsLab-modified versions of insulin that work faster or last longer, used to treat type 1 and type 2 diabetes.
- GlucagonEmergency hormone that quickly raises blood sugar during a severe hypo; also used to relax the gut during scans.